Literature DB >> 1812004

Anti-aldosteronergic effect of torasemide.

T Uchida1, K Yamanaga, M Nishikawa, Y Ohtaki, H Kido, M Watanabe.   

Abstract

The diuretic actions of torasemide and furosemide were studied in normotensive rats and in deoxycorticosterone acetate (DOCA)-saline-loaded hypertensive rats. Torasemide (0.3-3 mg/kg) and furosemide (3-30 mg/kg) had a dose-dependent and significant diuretic action in normotensive rats. Potassium retention was only observed in the case of torasemide. Torasemide also had a dose-dependent and significant diuretic action in DOCA-saline-loaded hypertensive rats, whereas furosemide did not. Higher doses of torasemide (10 mg/kg) and furosemide (100 mg/kg) increased both plasma renin activity and aldosterone concentration in normotensive rats in a similar manner. In vivo aldosterone receptor binding was determined to test the possible anti-aldosteronergic effect of torasemide. Torasemide inhibited the binding of aldosterone to its receptor in the cytoplasmic fraction of rat kidney in a dose-dependent manner, while furosemide produced no effect. These results suggest strongly that an anti-aldosteronergic action of torasemide contributes to producing less kaliuresis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1812004     DOI: 10.1016/0014-2999(91)90812-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

Review 1.  A reappraisal of loop diuretic choice in heart failure patients.

Authors:  Jonathan Buggey; Robert J Mentz; Bertram Pitt; Eric L Eisenstein; Kevin J Anstrom; Eric J Velazquez; Christopher M O'Connor
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

2.  Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure.

Authors:  S Kasama; T Toyama; T Hatori; H Sumino; H Kumakura; Y Takayama; S Ichikawa; T Suzuki; M Kurabayashi
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

Review 3.  New insights into combinational drug therapy to manage congestion in heart failure.

Authors:  Frederik Hendrik Verbrugge; Lars Grieten; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 4.  Diuretic Strategies in Acute Decompensated Heart Failure.

Authors:  E Ashley Hardin; Justin L Grodin
Journal:  Curr Heart Fail Rep       Date:  2017-04

5.  Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.

Authors:  Robert J Mentz; Jonathan Buggey; Mona Fiuzat; Mads K Ersbøll; Phillip J Schulte; Adam D DeVore; Eric L Eisenstein; Kevin J Anstrom; Christopher M OʼConnor; Eric J Velazquez
Journal:  J Cardiovasc Pharmacol       Date:  2015-05       Impact factor: 3.105

Review 6.  Loop Diuretics in the Treatment of Hypertension.

Authors:  Line Malha; Samuel J Mann
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

7.  4-(3-Methyl-anilino)-N-[N-(1-methyl-ethyl)carbamo-yl]pyridinium-3-sulfon-amidate (torasemide) methanol 0.25-solvate 0.25-hydrate.

Authors:  Gianluca Bartolucci; Bruno Bruni; Silvia A Coran; Massimo Di Vaira
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-04-08

Review 8.  Benefits and risks of torasemide in congestive heart failure and essential hypertension.

Authors:  D C Brater
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

9.  Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.

Authors:  Robert J Mentz; Eric J Velazquez; Marco Metra; Colleen McKendry; Karen Chiswell; Mona Fiuzat; Michael M Givertz; Adriaan A Voors; John R Teerlink; Christopher M O'Connor
Journal:  Future Cardiol       Date:  2015-09-25

10.  Torasemide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis.

Authors:  H Knauf; E Mutschler; H Velazquez; G Giebisch
Journal:  Eur J Clin Pharmacol       Date:  2009-02-20       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.